EUVIMEDEUVIMED entdecken
Crossref

Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases

Akihide Kobayashi, Kenji Ikemura, Eri Wakai, Masayoshi Kondo, Masahiro Okuda

Anticancer Research · 2023

DOI: 10.21873/anticanres.16764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Akihide Kobayashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Graduate School of Medicine, Osaka University, Suita, Japan. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Chemotherapy-induced peripheral neuropathy (CIPN) due to oxaliplatin (L-OHP) is a major clinical problem. Effective and safe preventive strategies for CIPN are urgently needed. Although proton pump inhibitors (PPIs) have various off-target effects, their clinical impact on L-OHP-induced CIPN remains unclear. In the present study, we investigated the effects of PPIs on L-OHP-induced CIPN in patients using two real-world clinical databases. PATIENTS AND METHODS: We retrospectively analyzed the electronic medical records of Osaka University Hospital to examine the effect of PPIs on CIPN development in 217 patients who received XELOX (L-OHP plus capecitabine) therapy for colorectal cancer. In addition, the Japanese Adverse Drug Event Report (JADER) database was used to validate the effects of PPIs on L-OHP-induced CIPN. RESULTS: The incidences of CIPN (grade ≥2) and discontinuation of L-OHP were significantly lower in patients with PPIs than in those without PPIs. Multivariate analysis showed that concomitant PPIs use was an independent factor that significantly contributed to the prevention of grade ≥2 CIPN (odds ratio=0.054, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Nervous System DiseasesColorectal NeoplasmsAntineoplastic AgentsHumansOxaliplatinProton Pump InhibitorsRetrospective Studies

Stichwörter der Autor:innen

Chemotherapy-induced peripheral neuropathydrug repositioningoxaliplatinproton pump inhibitors

Substanzen

OxaliplatinProton Pump InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Department of Pharmacy, Osaka University Hospital, Suita, Japan.
  • Department of Hospital Pharmacy, Graduate School of Medicine, Osaka University, Suita, Japan; ikemurak@hp-drug.med.osaka-u.ac.jp.
  • Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Division of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • Department of Hospital Pharmacy, School of Pharmaceutical Sciences, Osaka University, Suita, Japan.

Zitieren

APA

Kobayashi, A., Ikemura, K., Wakai, E., Kondo, M., & Okuda, M. (2023). Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases. Anticancer Research. https://doi.org/10.21873/anticanres.16764

Vancouver

Kobayashi A, Ikemura K, Wakai E, Kondo M, Okuda M. Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases. Anticancer Research. 2023. doi:10.21873/anticanres.16764

BibTeX
@article{Kobayashi2023,
  author = {Kobayashi, Akihide and Ikemura, Kenji and Wakai, Eri and Kondo, Masayoshi and Okuda, Masahiro},
  title = {Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16764}
}
Kostenlos starten →